



ersonal use only

# Investor Presentation

5<sup>TH</sup> MARCH 2025

# Disclaimer

This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

## Goal of Session

1. A review of the Rhythm's purpose and business goals
2. Summary of Rhythm's innovative ColoSTAT® program
3. Introduction to Rhythm's revenue-generating platform: geneType™
4. The value of Rhythm as a commercial organisation with a strong proprietary product pipeline

## Agenda

1. Rhythm Biosciences – a company transforming cancer diagnostics
2. Development of ColoSTAT®: Rhythm's opportunity to enter a blockbuster market
3. The acquisition of the Genetype assets: a strategically important event that accelerates commercial growth and expands the product portfolio into risk assessment and genomics
4. Strengthening the proteomic platform: new cancer biomarker programs commenced

**Note:** Genetype denotes the overall business and related assets whereas geneType™ denotes the product

# About Rhythm Biosciences



**Rhythm Biosciences is committed to saving lives through the evaluation of cancer risk and early detection of cancers**



---

Rhythm is a health innovator driven by the singular purpose of giving people the earliest possible chance to take control of their health.

---

Developing novel risk assessment and screening solutions for specific cancers via patient friendly tests.

---

A range of solutions that will allow the early detection of disease which gives individuals the best possible opportunity for favorable treatment outcomes.

---

Addressing large under-served global markets heavily supported by public and private health care systems.

---

Patent protected; fully characterised proteomic, genomic technology that can be readily adopted in routine laboratories.

---

**geneType™** commercially available now and **ColoSTAT®** anticipated commercial launch in 2H CY2025.




# Corporate overview



## CORPORATE SNAPSHOT

ASX Code	RHY
Share Price (4 <sup>th</sup> March 2025)	\$0.093
Shares on Issue	283,597M
Unlisted Options	21M
Market Capitalisation	\$25.5M
Cash in Bank (31 Dec. 2024)	\$4.37M
Top 20 Shareholders	42%

## SHARE PRICE CHART - ASX:RHY



## BOARD AND MANAGEMENT

**David Atkins, PhD**  
CEO & MD



Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry.

**Otto Buttula**  
Non-Executive Chairman



Extensive financial, investment, IT & biotech experience.

Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual

Formerly a Director of Imugene (ASX:IMU), Chairman of Investorfirst, now HUB (ASX: HUB), HITIQ (ASX: HIQ) & Oncosil Medical (ASX: OSL).

**Sue MacLeman**  
Non-Executive Director



30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SME's.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently NED at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, ATSE & OMICO & member of various industry, government & academic advisory committees.

**Gavin Fox-Smith**  
Non-Executive Director




38 years as a leader and champion of Medical Technology in Australia/NZ and Asia.

Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation.

Gavin was previously CEO of Omnigon, a private Australian company in the Ostomy Care market.

# Detecting cancer earlier and maintaining wellness

The power of the combination of the Rhythm and Genetype capabilities and portfolio



## Risk Assessment

Determination of risk profile

Personalised management of health



## Disease Screening

Non-invasive detection of disease

Early detection of disease

### A powerful combination enabling:

- Supports preventative measures to maintain wellness
- Increase the likelihood of earlier disease detection
- Promote better treatment outcomes for detected disease
- Potential use in drug clinical studies for patient stratification
- Potential for development as companion diagnostic tests

### Suitable for 100s millions of individuals/patients globally

**Example:** geneType™ bowel cancer risk assessment of the general population to help guide usage of ColoSTAT®. Potentially leads to improved screening compliance, earlier disease detection and improved outcomes.

Personal use only

# Half Year Highlights

- ✓ Significant progress achieved in 2nd Generation ColoSTAT<sup>®</sup> Multiplex Alpha Kit with **superior analytical results** compared to the 1st Generation Kit;
- ✓ Delivery of **2nd Generation ColoSTAT<sup>®</sup> Beta Release candidate** multiplex kits;
- ✓ **Board renewal** process commenced with **Dr David Atkins**, the Chief Executive Officer (CEO), joining the Board as Managing Director (MD). **Mr Gavin Fox-Smith** joined the Board on 2 December 2024 following the retirements of Dr Trevor Lockett and Mr Lou Panaccio;
- ✓ Receipt of **\$3.2m** Research & Development Tax Incentive (RDTI) return;
- ✓ Completion of a **placement for \$3.5m** (before costs);
- ✓ Transformational **acquisition of the Genetype** business assets catapulting Rhythm into a commercial organisation with the addition of the geneType<sup>™</sup> product portfolio;
- ✓ Positive progress in **platform expansion** activities.




# ColoSTAT<sup>®</sup> Development

---

ersonal use only

# Faster turnaround time, lower cost, updated & simplified ColoSTAT<sup>®</sup> Kit



ersonal use only

# ColoSTAT® 2025 Development Activities

	Key Activities	Next Steps
1	Assay Kit Verification	<ul style="list-style-type: none"><li>• Verification of kit analytical specification</li></ul>
2	Pilot Production	<ul style="list-style-type: none"><li>• Finalise kit transfer to manufacturing</li></ul>
3	Kit Analytical Validation Study	<ul style="list-style-type: none"><li>• Assay performance evaluation with patient samples and development of a detection algorithm</li></ul>
4	Algorithm Validation Study	<ul style="list-style-type: none"><li>• Validation of algorithm performance on additional patient samples</li></ul>
5	Commercialisation	<ul style="list-style-type: none"><li>• <b>Implementation &amp; validation of the system for commercial use with a commercial partner(s) under the 'In-House IVD' pathway</b></li></ul>



# Genotype Acquisition

---

ersonal use only

# Genotype acquisition by Rhythm



## Overview

- **Rhythm Biosciences** completed the asset acquisition agreement for the Genetype business assets.
- Business integration is complete.
- Genetype products are now commercially available, and sales recommenced.

## Acquisition Drivers

- Expanding our product scope to risk assessment supports the mission of early detection of cancer.
- Risk assessment and screening solutions are highly complimentary.
- The acquisition accelerates the business' commercial growth, broadens capability and expands the geographical footprint.
- The expanded multiomics capability of genomics and proteomics supports expansion of the Rhythm product portfolio.

## 2025 – Expected Outcomes

- Accelerated sales of the **geneType™** product platform.
- Expansion of the overall oncology product portfolio.

**Note:** Genetype denotes the overall business and related assets whereas geneType™ denotes the product

# About the geneType™ product

A leading genomic testing portfolio



- The **geneType™** product portfolio is a world-leading personalised predictive test portfolio that uses a unique combination of genomic and clinical information to predict risk of chronic disease development. See [www.genetype.com](http://www.genetype.com) for the full test menu and publications.
- geneType™ empowers individuals and physicians to improve health outcomes of people around the world enabling a new era of personalised medicine.
- The portfolio includes a patented **Multi Risk Test (MRT)** and Hereditary Breast and Ovarian Cancer (HBOC), a comprehensive breast and ovarian cancer test. Currently the HBOC test is only available in the US.
- MRT was launched in 2021 by Genetic Technologies in the US and Australia with 79.5% of tests providing novel health insights previously unknown.<sup>1</sup>

- geneType™ clinical performance has been established and published<sup>2</sup> with two examples being:
  - **Colorectal cancer:** Identifies significant numbers of individuals with risk equivalent to having a 1<sup>st</sup> degree relative with cancer.<sup>3</sup>
  - **Breast cancer:** identification of 4X more at-risk woman compared to traditional models.<sup>4</sup>
- geneType™ is currently protected by **25 granted patents** and 9 pending.
- Commercial traction with medical and payer B2B channels with several key partnerships close to finalisation.



Notes:  
1. Based on in-house reported results to end of May 2024 for the geneType MRT 79.5% of patient results demonstrated elevated risk for one or more diseases  
2. <https://genetype.com/for-medical-practitioners/the-science/>  
3. Gafni et al. PlosOne 2021; Spaeth et al. JCO 2023  
4. Spaeth et al. Can Prev Res 2023; Allman et al. Breast Cancer Res Treat 2023

# geneType™ opportunities for 2025

## Oncology Portfolio Focus


- Breast\*
- Prostate
- Colorectal\*
- Ovarian
- Melanoma
- Pancreatic\*



\* Rhythm protein biomarker program overlap.

## Customer Segments

- Health Care Professionals – B2B
- Strategic partners – B2B2B




## Geographical Priorities



\*see note

## Commercial Channels

- Direct
- Sales intermediaries and distributors
- Strategic partners



\*Example markets: flags represents geographies and new markets are to be determined



# 2025 Catalysts

---

ersonal use only

# Upcoming value inflection points

PRODUCT	ITEM	DESCRIPTION	ESTD. DELIVERY DATE
ColoSTAT®	Alpha Assay Ready	Arrival of Alpha kits for testing	☑
ColoSTAT®	Beta Release Candidate	Beta Kits ready for verification	☑
geneType™	Genetype business integration	Complete integration of Genetype organisation	☑
ColoSTAT®	Kit Validation Ready	Kit Verification completion, production kits ready	1H CY25
geneType™	geneType™ relaunch	Relaunch and growth acceleration of geneType product portfolio	1H CY25
ColoSTAT®	Commercialisation	ColoSTAT® Partner's In House IVD launch	2H CY25
ColoSTAT® & geneType™	Portfolio expansion	Update on protein and genomic product portfolio expansion	2H CY 25

ersonal use only



**Thank you!**

[david.atkins@rhythmbio.com](mailto:david.atkins@rhythmbio.com)

[www.rhythbio.com](http://www.rhythbio.com)